Industry

Partnership to focus on manufacturing clinical materials for future clinical studies PHILADELPHIA–(BUSINESS WIRE)–iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM … [Read more…]

With fundamental advancements made by the founding team, Terremoto’s lysine-based covalency platform holds the potential to expand the covalent drug alphabet and create both best-in-class and first-in-class small molecule medicines Financing co-led by renowned life-science investors OrbiMed and Third Rock Ventures SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based … [Read more…]

Open-Label Trial in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the first patient has been dosed in an open-label Phase 2 study evaluating ENV-101 (taladegib) in patients with advanced solid … [Read more…]

Company Reaches Milestone During Stroke Awareness Month, Serving as a Reminder to Learn the Signs of Stroke CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that 10,000 patients have been treated in the U.S. with its technologies for stroke since 2020. The company’s current portfolio includes the Zoom Stroke Solution™ and TracStar® LDP technologies for ischemic … [Read more…]

MENLO PARK, Calif.–(BUSINESS WIRE)–Frazier Life Sciences announced the addition of Tao Fu as a Venture Partner. He has over 25 years of business development, general management, operations, strategy, and commercial leadership experience in the pharmaceutical and biotech industry. Mr. Fu most recently served as President & Chief Operating Officer and then Chief Strategy Officer for … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor conferences: Cowen’s Virtual 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022. Fireside chat … [Read more…]

IRVINE, Calif.–(BUSINESS WIRE)–Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as well as its liquid biopsy profiles for both solid tumors and hematology that are designed to provide a wide range of clinically actionable insights about a patient’s tumor. The CE mark will allow GTC … [Read more…]

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The Company is also creating two corporate … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “2-Day Seminar on A to Z of Analytical Method Validation and Transfer” training has been added to ResearchAndMarkets.com’s offering. Reliable analytical results are necessary to make informed decision about the quality and safety of the products in the pharmaceutical industry. In addition, such analytical data are required for regulatory submissions in support of … [Read more…]

Merck Animal Health and Oval Park Capital continue strong support as valued investors MORRISVILLE, N.C.–(BUSINESS WIRE)–TARGAN (formerly Applied LifeSciences & Systems (ALSS)) announced today it has secured $35 million of Series C equity financing. The financing was co-led by Mountain Group Partners and NovaQuest Capital Management. Existing investors Merck Animal Health and Oval Park Capital … [Read more…]